These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 19552748

  • 1. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.
    Sakugawa T, Miura M, Hokama N, Suzuki T, Tateishi T, Uno T.
    Br J Clin Pharmacol; 2009 May; 67(5):535-40. PubMed ID: 19552748
    [Abstract] [Full Text] [Related]

  • 2. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers.
    Tateishi T, Miura M, Suzuki T, Uno T.
    Br J Clin Pharmacol; 2008 May; 65(5):693-700. PubMed ID: 18294330
    [Abstract] [Full Text] [Related]

  • 3. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
    Shimizu M, Uno T, Sugawara K, Tateishi T.
    Br J Clin Pharmacol; 2006 May; 61(5):538-44. PubMed ID: 16669847
    [Abstract] [Full Text] [Related]

  • 4. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
    Yasui-Furukori N, Uno T, Sugawara K, Tateishi T.
    Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527
    [Abstract] [Full Text] [Related]

  • 5. Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers.
    Akamine Y, Miura M, Yasui-Furukori N, Kojima M, Uno T.
    Br J Clin Pharmacol; 2012 Mar; 73(3):478-81. PubMed ID: 21950458
    [Abstract] [Full Text] [Related]

  • 6. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers.
    Kim KA, Park JY.
    Eur J Clin Pharmacol; 2010 Jul; 66(7):721-5. PubMed ID: 20306185
    [Abstract] [Full Text] [Related]

  • 7. Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers.
    Akamine Y, Miura M, Yasui-Furukori N, Ieiri I, Uno T.
    J Clin Pharm Ther; 2015 Feb; 40(1):98-103. PubMed ID: 25263393
    [Abstract] [Full Text] [Related]

  • 8. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
    Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD.
    Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
    [Abstract] [Full Text] [Related]

  • 9. Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics.
    Pinto L, Moreira FL, Nardotto GHB, Cavalli RC, Moisés ECD, Duarte G, Lanchote VL.
    Pharm Res; 2020 Jun 17; 37(7):131. PubMed ID: 32557079
    [Abstract] [Full Text] [Related]

  • 10. An update on the clinical pharmacokinetics of fexofenadine enantiomers.
    Akamine Y, Miura M.
    Expert Opin Drug Metab Toxicol; 2018 Apr 17; 14(4):429-434. PubMed ID: 29635947
    [Abstract] [Full Text] [Related]

  • 11. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers.
    Kim KA, Park PW, Park JY.
    Eur J Clin Pharmacol; 2009 Jun 17; 65(6):609-14. PubMed ID: 19221726
    [Abstract] [Full Text] [Related]

  • 12. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
    Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG.
    Clin Pharmacol Ther; 2005 Aug 17; 78(2):191-201. PubMed ID: 16084853
    [Abstract] [Full Text] [Related]

  • 13. Clinical pharmacokinetics of fexofenadine enantiomers.
    Miura M, Uno T.
    Expert Opin Drug Metab Toxicol; 2010 Jan 17; 6(1):69-74. PubMed ID: 19947891
    [Abstract] [Full Text] [Related]

  • 14. Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model.
    Pinto L, Bapat P, de Lima Moreira F, Lubetsky A, de Carvalho Cavalli R, Berger H, Lanchote VL, Koren G.
    Pharm Res; 2021 Apr 17; 38(4):647-655. PubMed ID: 33825113
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of fexofenadine enantiomers in healthy subjects.
    Miura M, Uno T, Tateishi T, Suzuki T.
    Chirality; 2007 Mar 17; 19(3):223-7. PubMed ID: 17230498
    [Abstract] [Full Text] [Related]

  • 16. Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe.
    Zhou Q, Ye Z, Ruan Z, Zeng S.
    J Ethnopharmacol; 2013 Apr 19; 146(3):744-9. PubMed ID: 23422332
    [Abstract] [Full Text] [Related]

  • 17. Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers.
    Saruwatari J, Yasui-Furukori N, Niioka T, Akamine Y, Takashima A, Kaneko S, Uno T.
    J Clin Psychopharmacol; 2012 Apr 19; 32(2):195-9. PubMed ID: 22367658
    [Abstract] [Full Text] [Related]

  • 18. Effects of breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers.
    Zhao Y, Miao Z, Jiang M, Zhou X, Lai Y.
    Xenobiotica; 2021 Mar 19; 51(3):366-372. PubMed ID: 33256506
    [Abstract] [Full Text] [Related]

  • 19. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
    Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF.
    Br J Clin Pharmacol; 2002 May 19; 53(5):526-34. PubMed ID: 11994059
    [Abstract] [Full Text] [Related]

  • 20. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers.
    Robbins DK, Castles MA, Pack DJ, Bhargava VO, Weir SJ.
    Biopharm Drug Dispos; 1998 Oct 19; 19(7):455-63. PubMed ID: 9818712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.